2 Alternative performance measures
In presenting and discussing DSM's financial position, operating results and net results, management uses certain Alternative performance measures not defined by IFRS. These Alternative performance measures (APMs) should not be viewed in isolation as alternatives to the equivalent IFRS measures and should be used as supplementary information in conjunction with the most directly comparable IFRS measures. Alternative performance measures do not have standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other companies.
To provide clear reporting on the developments of the business, APM adjustments are made that impact the EBIT(DA), net profit, ROCE and the EPS. A reconciliation of these Alternative performance measures to the most directly comparable IFRS measures can be found in the table Alternative performance measures.
The APM adjustments to net profit, as included in the APMs, can be specified as follows:
2019 | 2018 | |
APM adjustments: | ||
| 13 | - |
| - | (11) |
| 68 | 68 |
| 17 | 11 |
| 23 | 32 |
| (27) | (23) |
| (28) | (122) |
Total APM adjustments (income)/expense | 66 | (45) |
2019
The APM adjustments in 2019 are listed below:
Acquisition and divestment costs of €13 million relate mainly to the acquisition of Yimante, Andre Pectin and Royal CSK
Restructuring costs of €68 million relate to project costs of the restructuring projects together with the redundancy schemes associated with the dismissal of employees and costs of termination of contracts
The other APM adjustment of €17 million relates to the provision for soil cleaning within Corporate Activities
Impairments of property, plant and equipment (PPE) and intangible assets of €23 million relate mainly to a development project of DSM Nutritional Products and the impairment of an investment project within DSM Food Specialties
APM adjustments to the result from associates and joint ventures of €28 million mainly relate to the step-up to the fair value of the associate Andre Pectin prior to the acquisition
2018
The APM adjustments in 2018 are listed below:
Restructuring costs of €68 million relate to project costs of the restructuring projects together with the redundancy schemes associated with the dismissal of employees and costs of termination of contracts
The other consolidation change relates to the deconsolidation of Yantai Andre Pectin, which led to an accounting profit of €11 million
The other APM adjustments of €11 million relate to a changed and remeasured earn-out arrangement with Amyris Brasil
Impairments of property, plant and equipment (PPE) and intangible assets of €32 million relate mainly to an R&D building of DSM Nutritional Products in Switzerland and the impairment of a development project within DSM Food Specialties
APM adjustments to the result from associates and joint ventures mainly relate to the gain on the sale of the 50% share in DSM Sinochem Pharmaceuticals (DSP) of €109 million and the gain on the sale of the shares in Essential Medical of €13 million
Alternative performance measures
2019 | 2018 | |
Operating profit | 954 | 1,245 |
Depreciation, amortization and impairments | 632 | 509 |
EBITDA | 1,586 | 1,754 |
APM adjustments to EBITDA: | ||
| 13 | - |
| - | (11) |
| 68 | 68 |
| 17 | 11 |
Total APM adjustments | 98 | 68 |
Adjusted EBITDA | 1,684 | 1,822 |
Operating profit | 954 | 1,245 |
APM adjustments to Operating profit: | ||
| 98 | 68 |
| 23 | 32 |
Total APM adjustments | 121 | 100 |
Adjusted operating profit | 1,075 | 1,345 |
Profit for the year | 764 | 1,079 |
APM adjustments to: | ||
| 121 | 100 |
| (28) | (122) |
Income tax related to APM adjustments | (27) | (23) |
Total APM adjustments | 66 | (45) |
Adjusted net profit | 830 | 1,034 |
Profit attributable to non-controlling interests | (7) | (2) |
Dividend on cumulative preference shares | (8) | (8) |
Adjusted net profit available to holders of ordinary shares | 815 | 1,024 |
Earnings per share | ||
Average number of ordinary shares outstanding (x 1,000) | 175,731 | 175,323 |
Effect of dilution due to share options (x 1,000) | 1,088 | 1,000 |
Adjusted average number of ordinary shares outstanding (x 1,000) | 176,819 | 176,323 |
Earnings per share (EPS) (in €): | ||
| 4.27 | 6.10 |
| 4.24 | 6.06 |
| 4.64 | 5.84 |
| 4.61 | 5.81 |
Alternative performance measures
2019 | 2018 | ||
Capital employed | |||
---|---|---|---|
Intangible assets | 3,515 | 3,090 | |
Property, plant and equipment | 4,040 | 3,511 | |
Investment grants / drawing rights | (96) | (94) | |
Inventories | 2,019 | 1,993 | |
Current receivables | 1,698 | 1,738 | |
Current liabilities | (1,865) | (2,057) | |
Capital employed at 31 December | 9,311 | 8,181 | |
Average capital employed | |||
Capital employed at 1 January | 8,3961 | 7,766 | |
Capital employed at 31 March | 8,907 | 7,740 | |
Capital employed at 30 June | 8,735 | 8,115 | |
Capital employed at 30 September | 9,330 | 8,220 | |
Capital employed at 31 December | 9,311 | 8,181 | |
Average capital employed | 8,936 | 8,004 | |
Adjusted operating profit | 1,075 | 1,345 | |
ROCE in % | 12.0 | 16.8 | |
Cash provided by operating activities | 1,385 | 1,391 | |
Cash impact APM adjustments | 57 | 94 | |
Capital expenditure | (627) | (673) | |
Payments regarding drawing rights | (14) | (20) | |
Financial lease IAS 17 (2018) | - | 18 | |
Adjusted net operating free cash flow | 801 | 810 |